Boehringer
Boehringer targets AML
March 1, 2013Research and Development, Sales and Marketing AML, Boehringer
Boehringer Ingelheim is to begin a pivotal trial of its investigative treatment volasertib in patients with acute myeloid leukaemia (AML). …
J&J seeks end to Doxil shortage as Ben Venue signs consent decree
January 28, 2013Manufacturing and Production Ben Venue, Boehringer, Caelyx, Doxil, J&J, JJ, Janssen
Johnson & Johnson says it has taken steps to establish new supplies of its cancer drug Doxil/Caelyx, which remains in …
Boehringer in oncology tie-up
January 16, 2013Research and Development, Sales and Marketing Boehringer, Cancer, horizon, x-man
Boehringer Ingelheim has entered a five-year tie-up with a UK biotech company which specialises in helping research into personalised medicines. …
Boehringer hands back Lilly drug
January 8, 2013Research and Development, Sales and Marketing Boehringer, Tradjenta, diabetes, lilly
Boehringer Ingelheim has handed back one of Eli Lilly’s investigational diabetes drugs as a result of ‘independent strategic portfolio considerations’. …
Boehringer to make cancer antibody for Apexigen
December 11, 2012Manufacturing and Production, Sales and Marketing APX005, Apexigen, Boehringer
Boehringer Ingelheim has won a contract from US biotech company Apexigen to manufacture APX005, an antibody-based drug candidate for various …
Trajenta may reduce stroke damage
December 4, 2012Research and Development, Sales and Marketing Boehringer, EMA, Trajenta, diabetes, linagliptin
Boehringer Ingelheim’s diabetes drug Trajenta could one day be used to minimise the effects of brain damage following stroke. Scientists …
Pharma manufacturing news in brief
November 20, 2012Manufacturing and Production Alfa Laval, Boehringer, Fujifilm, Health Canada, Novartis
Our latest round-up of manufacturing news includes a facility contract for Alfa Laval, plus updates from Fujifilm, Novartis, Boehringer Ingelheim …
New plant positions Lilly for changing insulin market
November 6, 2012Manufacturing and Production Boehringer, insulin, lilly
Eli Lilly has unveiled plans for a $140 million expansion of its insulin plant in Indianapolis as it starts to …
Digital Pharma: what should we talk about?
October 8, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer, Facebook, Pfizer, digital pharma, social media, twiiter
The received wisdom today among the ‘digirati’ is that the pharmaceutical industry must join in the online conversation, and to …
Boehringer closing Petersburg API plant
September 25, 2012Manufacturing and Production API, Boehringer, Petersburg, chemicals
Boehringer Ingelheim has decided to close down one of its active pharmaceutical ingredient (API) manufacturing facilities in the US because …
Boehringer submits new lung cancer drug
September 20, 2012Research and Development, Sales and Marketing Boehringer, NSCLC, Roche, Tarceva, afatinib
Boehringer Ingelheim has filed its new lung cancer drug with the EMA. Afatinib is the latest targeted therapy for lung …
Boehringer says it is rolling out ‘fully disposable’ biomanufacturing
September 18, 2012Manufacturing and Production Boehringer, CMO, GMP, SUSs
Boehringer Ingelheim says it has developed a production platform for biopharmaceuticals that makes full use disposable technologies both upstream and …
Boehringer beta launches Syrum on Facebook
September 17, 2012Medical Communications, Sales and Marketing Boehringer, Facebook, Syrum
Boehringer Ingelheim has announced the beta launch of its first social game on Facebook, the eagerly-awaited Syrum. Other sectors have …
Online programme to help diabetes patients
September 14, 2012Medical Communications, Sales and Marketing Boehringer, diabetes, lilly
Boehringer Ingelheim and Eli Lilly have launched an online initiative which they say will help diabetes sufferers make simple lifestyle …
Boehringer signs diabetes research deal
September 7, 2012Sales and Marketing Boehringer, diabetes, obesity
Boehringer Ingelheim has signed a four-year research agreement with a top Swiss university to look at the underlying causes of …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
